Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure)

The summary for the Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure): The purpose of this limited competition Funding Opportunity Announcement (FOA) is to support the continuation and expansion of the existing NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. This FOA requests applications for a cooperative agreement research grant (U24) to serve as the Network Management Core (NEMO) for the PTC. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that will test innovative disease modifying therapies (DMT) for adult chronic lung diseases. NEMO will have primary responsibility for organizing and operating this multi-center cooperative.

Federal Grant Title:	Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-21-012
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.838
CFDA Descriptions:	Information not provided
Current Application Deadline:	July 24th, 2020
Original Application Deadline:	July 24th, 2020
Posted Date:	April 30th, 2020
Creation Date:	April 30th, 2020
Archive Date:	August 29th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 1st, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-012.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...